MarketPulse

Tecvayli

2 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Johnson & Johnson

J&J Seeks EMA Approval for TECVAYLI as First-Line Monotherapy in Multiple Myeloma

Johnson & Johnson submits EMA application for TECVAYLI monotherapy in relapsed/refractory multiple myeloma, citing 71% risk reduction in disease progression or death versus standard care.
JNJEMA approvalPhase 3 trial
BenzingaBenzinga··Vandana Singh

J&J Wins FDA Nod for Multiple Myeloma Combo with Blockbuster 83% Survival Rate

FDA approves J&J's Tecvayli plus Darzalex Faspro for multiple myeloma with 83.3% three-year survival rate, expanding drug's label.
JNJPhase 3 clinical trialFDA approval